Merck releases updated KEYTRUDA data
Merck has released updated data from two clinical trials designed to assess KEYTRUDA (pembrolizumab), its anti-PD-1 therapy developed to treat patients who have relapsed or refractory classical Hodgkin lymphoma (cHL). Read More »